Scribe and Eli Lilly Reach Second Milestone in In Vivo CRISPR Collaboration
BioPharmaTrend
|
February 17, 2026
X min read
BioPharmaTrend
|
February 17, 2026
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
